Literature DB >> 1403845

Comparison between new saliva stimulants in patients with dry mouth: a placebo-controlled double-blind crossover study.

A Aagaard1, S Godiksen, P T Teglers, M Schiødt, U Glenert.   

Abstract

Two new saliva stimulants: V6 and a mucin containing chewing gum were tested in this placebo-controlled double-blind crossover study. Forty-three patients (mean age 63 yr) complaining of dry mouth participated. The products were administered in a randomized order, and used for 2 wk each. The effect was evaluated by interviews and by determining changes in stimulated and unstimulated saliva flow rates. A positive effect was reported by 64%, 44%, and 26% of the patients using the mucin chewing gum, V6, and the placebo, respectively. More than 2/3 of the patients found the mucin chewing gum efficient at various times and situations. Sixty-one percent of the patients preferred the mucin chewing gum, 21% V6, and 5% the placebo product. Fifty percent of the patients had an increase in unstimulated salivary secretion rate from all products after 14 days regular use indicating a long-term effect.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1403845     DOI: 10.1111/j.1600-0714.1992.tb01369.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  8 in total

Review 1.  Topical and systemic medications for the treatment of primary Sjögren's syndrome.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Antoni Sisó-Almirall; Xavier Bosch; Athanasios G Tzioufas
Journal:  Nat Rev Rheumatol       Date:  2012-05-01       Impact factor: 20.543

Review 2.  Rational drug therapy recommendations for the treatment of patients with Sjögren's syndrome.

Authors:  P Oxholm; J U Prause; M Schiødt
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 3.  Treatment of oral dryness related complaints (xerostomia) in Sjögren's syndrome.

Authors:  W A van der Reijden; A Vissink; E C Veerman; A V Amerongen
Journal:  Ann Rheum Dis       Date:  1999-08       Impact factor: 19.103

4.  The Effect of a Combination Saliva Substitute for the Management of Xerostomia and Hyposalivation.

Authors:  R C Lapiedra; G E Gómez; B P Sánchez; A A Pereda; M D Turner
Journal:  J Maxillofac Oral Surg       Date:  2015-03-14

Review 5.  Contribution of HIV Infection, AIDS, and Antiretroviral Therapy to Exocrine Pathogenesis in Salivary and Lacrimal Glands.

Authors:  Imran Nizamuddin; Peter Koulen; Carole P McArthur
Journal:  Int J Mol Sci       Date:  2018-09-13       Impact factor: 5.923

6.  Preliminary Comparative Study of Oral7® Versus Salt-Soda Mouthwash on Oral Health Related Problems and Quality of Life among Head and Neck Cancer Patients Undergoing Radiotherapy.

Authors:  Norsa'adah Bachok; Biswa Mohan Biswal; Noor Hayati Abdul Razak; Wan Mohd Nazri Wan Zainoon; Kasmawati Mokhtar; Roselinda Abdul Rahman; Mohd Faizal Abdullah; Siti Mimi Nadiya Mustafa; Nawi Noza
Journal:  Malays J Med Sci       Date:  2018-10-30

Review 7.  A Review on Xerostomia and Its Various Management Strategies: The Role of Advanced Polymeric Materials in the Treatment Approaches.

Authors:  Afroditi Kapourani; Konstantinos N Kontogiannopoulos; Alexandra-Eleftheria Manioudaki; Athanasios K Poulopoulos; Lazaros Tsalikis; Andreana N Assimopoulou; Panagiotis Barmpalexis
Journal:  Polymers (Basel)       Date:  2022-02-22       Impact factor: 4.329

8.  Saliva substitute mouthwash in nasopharyngeal cancer survivors with xerostomia: a randomized controlled trial.

Authors:  Dayaabaran Marimuthu; Kong Min Han; Mohd Shawal Firdaus Mohamad; Mawaddah Azman
Journal:  Clin Oral Investig       Date:  2020-11-11       Impact factor: 3.573

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.